GAO: FDA's Mifeprex approval 'consistent'

Share this article:
The Government Accountability Office said the FDA's approval process for Mifeprex, the RU-486 abortion pill, was “consistent with the processes for the other Subpart H restricted drugs,” and its post-market oversight also has been consistent with other such drugs that have special distribution and administration controls. 

The GAO report was issued in response to a congressional inquiry from Sen. Mike Enzi (R-WY) based on lingering suspicions that the drug's approval was politically coerced by the Clinton administration. The GAO said critics have questioned aspects of the Mifeprex approval process, including the reliance on historically controlled clinical trials that compare a drug's effects on a condition rather than to another drug or placebo.

Critics said that Mifeprex does not fit within the scope of Subpart H, which applies to drugs that treat serious or life-threatening illnesses. And concerns have been raised about the agency's post-marketing oversight, including its response to deaths in women who took the drug. The GAO reports the FDA reviewed the NDA through three review cycles.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?